ClinGen RASopathy Variant Curation Expert Panel

Start Date	Your Name	Do you work for a laboratory that offers fee-for-service testing related to the work of your Expert Panel?	Have you made substantial contributions to the literature implicating a gene:disease relationship that relates to the work of your Expert Panel?		existing or planned independent curation efforts that will potentially overlap with the scope of your ClinGen work? If so, please describe:	Please disclose any other relevant conflicts of interest (e.g. patents, intellectual property ownership, or paid consultancies related to any variants or genes associated with the work of your Expert Panel):
	Open-Ended Response	Response	Response	If yes, please list the genes:	Open-Ended Response	Open-Ended Response
3/14/19	Kate Garber	Yes	No		There is the potential for publications related to EGL Genetic's particular areas of expertise, summarizing results from our panels.	
3/14/19	Mitchell W. Dillon	Yes	No	*I have a few abstracts out there, but no formal publication about a gene:disease relationship. The two publications below may be considered? PubMed: 27753652 PubMed: 26918529	None.	None.
3/14/19	Katherine Rauen, MD, PhD	No	No		no	none
3/14/19	Jennifer Lee	Yes	No		No other major curation efforts are planned, other than the individual variant classification needed for clinical samples for which RASopathy testing is ordered.	
2/4/19	Matthew Avenarius	Yes	No		N/A	N/A
2/2/19	Hélène Cavé	Yes	Yes	CBL PTPN11	no	none
1/25/19	Martin Zenker	Yes	Yes	PTPN11, SOS1, KRAS, NRAS, SHOC2, CBL, BRAF, MAP2K1, MAP2K2, RIT1, RRAS, HRAS, NF1		
1/24/19	Lisa Vincent	Yes	No		No	none
1/24/19	Bruce Gelb	No	Yes	PTPN11, SOS1, RAF1, SHOC2, SOS2, NRAS, KRAS		My institution has a patent for the PTPN11 discovery for Noonan syndrome and receives royalties for PTPN11, RAF1, SOS1 and SHOC2, for which I receive a share.
1/24/19	Heather Mason-Suares	Yes	No		No.	
1/23/19	Brad Williams	No	No			